NCT06384976Phase 2Active not recruiting

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Study sponsor: Kyverna Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-04Estimated
Enrollment · participants120Estimated
Source updated2025-01-13Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview